Avricore Health Inc. announced its agreement with Ascensia Diabetes Care, a global diabetes care company, to integrate their blood glucose monitoring (BGM) systems, marketed as CONTOUR®NEXT GEN and CONTOUR®NEXT ONE, with Avricore?s pharmacy-based point-of-care testing (POCT) platform, HealthTab. Ascensia Diabetes Care is a subsidiary of PHC Holdings Corporation (TSE 6523). The partnership?s objective is to support patients and pharmacists in Canada in better managing diabetes by linking the daily blood glucose testing results and pattern history data collected via the CONTOUR®NEXT GEN or CONTOUR®NEXT ONE meter the patient uses to the patient?s HealthTab account.

The partnership also seeks to support utilization of each technology by opening discussions related to collaborative communications to ensure patients and pharmacists are able to take advantage of what these data insights offer. Combining these new daily data insights from the patient?s BGM with the results, such as the patient?s HbA1c and lipids profile collected during the patient?s regular consultations with their pharmacist utilizing HealthTab and its associated instruments, this collaboration will deliver a more robust personal health data tool for the fight against diabetes, which affects 1 in 10 adults around the world (Source).